Department of Health and Human Services
Part 1. Overview Information
Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Funding Opportunity Title

Urinary Stone Disease Research Network: Scientific Data Research Center (USDRN-SDRC) (Collaborative U01)

Activity Code

U01 Research Project – Cooperative Agreements

Announcement Type

New

Related Notices

None

Funding Opportunity Announcement (FOA) Number

RFA-DK-15-005

Companion Funding Opportunity

RFA-DK-15-004, U01 Research Project – Cooperative Agreements

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.847   

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to establish a multi-center, multi-disciplinary group of investigators to be known as the Urinary Stone Disease Research Network (USDRN). This FOA solicits applications for the Scientific Data Research Center (SDRC) and runs in parallel with a separate FOA that invites applications for the Clinical Centers (CCs) (RFA-DK-15-004). The USDRN will a) design and conduct a randomized clinical trial (RCT) to investigate the impact of increased fluid intake and increased urine output on the rate of recurrence of urinary stones in adults and children, b) conduct clinical research to understand and mitigate ureteral stent-related pain and symptoms, and c) provide data and collect biological samples from the studies to create a resource for future researchers. RFA-DK-15-004 will support USDRN Clinical Centers.

Key Dates
Posted Date

August 24, 2015

Open Date (Earliest Submission Date)

October 18, 2015  

Letter of Intent Due Date(s)

October 18, 2015  

Application Due Date(s)

November 18, 2015, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable

Scientific Merit Review

February/March 2016

Advisory Council Review

May 2016

Earliest Start Date

July 2016

Expiration Date

November 19, 2015

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.


Table of Contents

Part 1. Overview Information
Part 2. Full Text of the Announcement

Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information


Part 2. Full Text of Announcement
Section I. Funding Opportunity Description

This FOA invites collaborative U01 cooperative agreement applications to establish a multi-center, multi-disciplinary group of investigators to be known as the Urinary Stone Disease Research Network (USDRN). The Scientific Data Research Center applications submitted under this FOA are linked to RFA-DK-15-004, which will support the USDRN clinical centers.

Urinary Stone Disease (USD) is an important healthcare problem affecting about 1 out of 11 Americans, causing pain and suffering for the patient and a financial burden for the Nation. The prevalence of USD in the US has nearly doubled in the last 15 years, and is increasing in both adults and children. According to the Urological Diseases in America (UDA) project funded by the NIDDK, the annual cost of USD is estimated at $10 billion making it the most expensive non-malignant urologic condition in the U.S. A recent study estimates that the impact of obesity, diabetes and population rates will increase costs of USD to $1.24 billion/year by 2030. An acute symptomatic episode of USD is generally extremely painful and frequently results in Emergency Department (ED) care. ED visit rates for USD have doubled between 1992 and 2009. Computed tomography use for evaluation of USD in ED has tripled during the same time period and use of drugs has also increased. Cross sectional analyses show that about 10% of ED visits for USD are for repeat encounters. The intangible costs to the affected individual and the family, such as pain, diminished quality of life (QoL), time-off from work or school, and professional risks caused by a renal colic are enormous.

The treatment of USD has advanced over the last 30 years. New endourologic approaches allowed most stones to be treated endoscopically without the need for a skin incision. Technical advances have improved surgical USD treatment strategies. Improved optic lens systems and fiberoptic light sources have enabled better visualization. Increased instrument flexibility and miniaturization along with effective energy sources for stone disintegration led to the development of percutaneous nephrolithotomy and ureteroscopic lithotripsy. Extracorporeal shock wave lithotripsy (SWL) was developed for stone fragmentation without invasive instrumentation of the body. Although SWL and endourologic approaches are commonly used for the treatment of an USD episode, there is a major trend towards more frequent use of ureteroscopy (URS). Medical management has also advanced to a certain extent; however the prevalence of USD continues to increase both in adults and children. Despite these advances the limited state of knowledge for USD is reflected in several clinical management guidelines that have been published by the American Urological Association (AUA), and European Association of Urology (EAU) using systematic reviews and data extraction. Only 1 of 27 and 3 of 17 recommendations were based on Level 1 evidence.

USD is often recurrent.  Data from the National Health and Nutrition Examination Survey (NHANES) show that 35% of participants had experienced 2 or more distinct episodes of urinary stones. Other epidemiologic data show that recurrence rates of first time stone formers at 2, 5, 10, and 15 years were 11%, 20%, 31%, and 39%, respectively. Thus prevention of USD recurrence could substantially reduce its public health burden.

Ureteral stenting is a common prophylactic procedure after URS to mitigate peri-operative complications. Stenting the ureter is also performed in conjunction with SWL, and after complicated percutaneous nephrolithotomy (PCNL). Ureteral stenting is also used for therapeutic purposes such as obstructive pyelonephritis, bilateral obstructing stones or an obstructing stone in a solitary kidney. However; ureteral stents cause considerable patient discomfort such as pain, dysuria, urinary frequency, incontinence and hematuria.

The goals outlined in this FOA were developed in part, from the NIDDK sponsored workshop "Urinary Stone Disease: Research Challenges and Opportunities" held on April 1-2, 2015.

Research Objectives

This FOA will establish a network of investigators to design and conduct clinical research studies in adults and children with USD. The network is expected to include a wide range of expertise including but not limited to adult and pediatric urologists, adult and pediatric nephrologists, pediatricians, ED physicians, clinical trialists, nutritionists, behavioral scientists and radiologists. All studies proposed in the applications will be a starting point for discussions regarding the research undertaken by the network. USDRN investigators will devise studies that will be reviewed by a Protocol Review Committee (PRC) and approved by the NIDDK, then recruit stone forming patients for the collaborative studies. The final study protocol will be designed by the Clinical Center, and Scientific Data Research Center Program Directors/Principal Investigators and approved by the Steering Committee. Network study results are expected to provide evidence for management approaches to USD.

USD has different causes, and there have been many studies to understand the mechanisms of stone formation and prevention of new episodes of USD. In contrast, there is scant information about recurrent episodes of USD.  Available evidence suggests a high (about 35%) and unchanging rate of recurrence. Most urinary stones are primarily composed of calcium. There is a need to identify the underlying causes and to improve methods to prevent calcium USD recurrences. Increasing fluid intake and urinary volume, and medical therapies with potassium citrate and/or thiazide or thiazide analog diuretics are the recommended measures for recurrent calcium stone prevention based on moderate quality of evidence.

Although increasing fluid intake is generally recommended for stone-forming patients, a Cochrane review found no studies of increased fluid intake for the primary prevention of USD, and only one study for secondary prevention (to reduce recurrence). A more recent systematic review and meta-analysis including observational studies demonstrated that increased fluid intake significantly reduced incident and recurrent stones. Adherence and safety data were limited. Thus there is a need for a definitive randomized clinical trial (RCT) to evaluate the impact of increased fluid intake on urinary stone recurrence. However, increasing fluid intake and maintaining a daily urine volume of at least 2.5 liters is very challenging in children and adults. There are no reliable recommendations on fluid intake in children. Reluctance to drink increased amounts of water, urinary symptoms due to higher urine volumes, environmental circumstances for bathroom breaks, potential hyponatremia causing altered mental status, confusion, and even seizures, and difficulties in behavior change are some of the impediments for uninterrupted and sustained high fluid intake. The use of wearable devices, smartphone applications and incentives to encourage fluid intake, methods to monitor urine volume, pH and specific gravity are some of the new methods that can be used to facilitate fluid intake. A RCT with sufficient power is needed to determine how to maintain high fluid intake, and then show whether increasing and maintaining urinary volume decreases the urinary stone recurrences in adults and children. Investigators are encouraged to think broadly on incorporating mobile health technology, behavioral economics and/or other innovative strategies to maintain long-term fluid intake. Applicants are also encouraged to propose innovative trial methodologies such as adaptive and pragmatic trial designs, and use of surrogates for stone recurrence.

Ureteral stents are commonly used for therapeutic or prophylactic purposes. Their use is frequently based on clinical judgment of the surgeon to improve stone passage and/or prevent complications rather than evidence. Despite their clinically utility, ureteral stents can cause significant patient pain and discomfort. Years of research by academia and industry to reduce patient discomfort by different stent designs, developing drug-coated stents, and using different stent materials, have not completely eliminated stent related symptoms. Some of the pain and stent related symptoms can be controlled or reduced by medications. Studies are needed to provide evidence for appropriate stent use of ureteral stents during common procedures for stones (SWL, URS, and PCNL), identify patients who will likely experience stent related pain and symptoms, and to mitigate those symptoms. These questions may be answered by establishing new patient cohorts, randomized clinical trials, pragmatic clinical trials or by using other novel clinical study methodologies. Applicants may propose integrated approaches such as an observational study for event rate and risk identification, and a RCT to reduce ureteral stent use and/or mitigate stent pain and symptoms. 

The long-term goal of USDRN is to inform clinical practice by a) providing evidence on the effects of fluid intake on urinary stone recurrence, b) understanding and reducing pain and suffering from the use of ureteral stents in USD patients, and c) to create data and biological specimen resources for USDRN investigators and other future researchers.

The Network Structure

The USDRN will consist of one Scientific Data Research Center (SDRC) and 3 to 5 Clinical Centers (CC). The SDRC and CC investigators will work collaboratively for the planning, execution and analysis of USDRN studies. The SDRC will be primarily responsible for insuring the scientific integrity and robustness of the research design, biostatistics, data quality, implementation, and data analysis of all study protocols. The SDRC biostatisticians work with the Clinical Center investigators to develop the scientific design of the study. The SDRC investigators have primary responsibility for ensuring that the design of the studies, including the primary outcome, is scientifically sound and is supported by appropriate power calculations. The SDRC provides biostatistical and analytic expertise and conducts analysis and interpretation of the laboratory and clinical data in conjunction with the investigators at the Clinical Centers. The SDRC is responsible for guiding development of the statistical analysis plan for the studies, and for each manuscript reporting pre-specified primary and secondary outcomes. The SDRC is also responsible for coordination of CC activities, subject confidentiality, safety, training/certification of study staff, and maintains and update the manual of operations. The SDRC is also responsible for movement of biological samples, and deposition of data and samples in the NIDDK Repository.

The major scientific responsibilities of the Scientific Data Research Center include the following:

  • Provide research study design, biostatistical, and implementation expertise for all USDRN studies.
  • Ensure the scientific integrity and robustness of the research design, statistical design, implementation, adherence, data quality, and data analysis of all study protocols.
  • Handle research design, statistical, implementation, and data analysis issues for a wide range of clinical studies including but not limited to RCTs, observational studies, pragmatic trials and biomarker studies.
  • Handle subject confidentiality and safety
  • Conduct training and certification of study staff, and maintain and update the manual of operations.
  • Monitor the implementation of the studies including adherence and data quality, and perform interim and final data analysis for each of the activities and studies undertaken.
  • Prepare databases of all data collected by CCs, perform quality control and statistical analyses, and coordinate, tract and assist all publications.
  • Work collaboratively with the USDRN Clinical Center PDs/PIs in planning and conducting the various research efforts undertaken by the USDRN and provide the organizational and administrative leadership necessary to enable the Network to function smoothly.
  • Coordinate all Steering Committee meetings, including in-person, telephone conference calls and webinars, establish and maintain USDRN public and private websites.
  • Coordinate all NIDDK appointed Data Safety and Monitoring Board, External Expert Panel or Protocol Review Committee meetings in addition to preparation of reports and presentations for the External Expert Panel and other meetings as needed.
  • Lead a scientific research pilot and feasibility research and ancillary studies program for non-network and USDRN investigators if needed.
Administration and Meetings

The USDRN Steering Committee (SC) will be composed of the SDRC and CC Program Directors/Principal Investigators (PDs/PIs), other key investigators and the NIDDK Project Scientist.  The SC will meet regularly in-person and by telephone conferences as a full committee and in working groups to develop and implement study protocols. The SC will review progress of individual studies, assess and evaluate results, interpret findings, and develop manuscripts for peer reviewed publications.  NIDDK will select chair(s) of the SC (Steering Committee Chair [SCC]) either from the PDs/PIs of the CC's or outside the study group. An Executive Committee (EC) will be comprised of the SCC(s), the SDRC PDs/PIs, and the NIDDK Project Scientist. Additional USDRN investigators, NIDDK Program Officers and support personnel will be a part of the EC as needed.  The Executive Committee will make operational decisions for the USDRN between SC meetings by means of weekly telephone conference calls. The NIDDK Project Scientist will assist the SC in the development of USDRN study protocols; will monitor the progress of projects and functioning of all network activities; will assist investigators in the analysis and interpretation of USDRN data; will aid in preparation of manuscripts for publication.

The NIDDK will appoint a Data Safety and Monitoring Board (DSMB) to serve as Protocol Review Committee (PRC) and External Experts Panel (EEP) as needed to provide input on the design of studies prior to their implementation, monitor the research efforts and the progress of the studies, and advise the NIDDK and USDRN investigators. CC and SDRC applicants must not suggest potential participants for this committee in their applications.

The first in-person USDRN Steering Committee Meeting will be a 2 day meeting held on 2 consecutive days within 2 months after the inception of the network in Washington, DC metro area.  Specific dates will be determined once the USDRN sites are awarded. Subsequent 1-2 day in-person SC meetings will be conducted every 3 months or as needed thereafter.

A Funding Opportunity Announcement information delivery conference call is scheduled for October 14, 2015 between 11:00 a.m. and 12:00 p.m. Eastern Standard Time to describe and explain the objectives, expected structure and functioning of USDRN.  Additional conference calls may also be held. Participation in this conference all is not required for application submission.  

Section II. Award Information
Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.

Application Types Allowed

New

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

Funds Available and Anticipated Number of Awards

NIDDK intends to commit $4 million in fiscal year 2016 to support two related funding opportunities, RFA-DK-15-005 and RFA-DK-15-004. NIDDK anticipates awarding one Scientific Data Research Center under this FOA, and 3-5 Clinical Centers under the companion RFA-DK-15-004. Future year amounts will depend on annual appropriations.

Award Budget

Application budgets are limited to $700,000 direct costs for the Scientific Data Research Center.

Award Project Period

The maximum project period is 5 years. 

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.

Section III. Eligibility Information
1. Eligible Applicants
Eligible Organizations

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)
  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession

Other

  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations
  • Non-domestic (non-U.S.) Entities (Foreign Institutions)
Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Required Registrations

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

  • Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
  • System for Award Management (SAM) (formerly CCR) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM. 
  • eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

This FOA only supports linked applications. Multiple PDs/PIs are allowed on any single application. Because the FOA already supports a team approach between groups of experts across sites and collaborating applications, the designation of multiple PDs/PIs on a single application may be less likely to apply. PD(s)/PI(s) from each linked application should not be designated as multiple PDs/PIs on each application of a collaborative set.   

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility
Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time.  This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).
Section IV. Application and Submission Information
1. Requesting an Application Package

Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the "Apply for Grant Electronically" button in this FOA or following the directions provided at Grants.gov.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity

The letter of intent, preferably electronically, should be sent to:

Francisco O. Calvo, Ph.D.
Chief, Review Branch
Division of Extramural Activities, NIDDK

6707 Democracy Boulevard, Room 752, MSC 5452
Bethesda, MD 20892-5452
(for express/courier service: Bethesda, MD 20817

Telephone: 301-594-8897

Fax: 301-480-3505

Email: calvof@mail.nih.gov

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed,

Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed , with the following modifications:

Descriptive Title of Applicant's Project: To allow NIH to identify a group of applications as a related set of collaborative applications, the titles for each application in the set must have the following format: a "1/N" indicator + Identical Title (e.g., "1/3", where the 1/3 means this is site 1 of 3 sites in the set. A set of applications is defined as all applications submitted in response to this FOA as well as the companion FOA (RFA-DK-15-004). Titles of all collaborative applications must be identical except as follows: Applications submitted in response to this FOA must include "Scientific Data Research Center" at the end of the title; the application submitted in response to RFA-DK-15-004 should include "Research Project" at the end of the title.  The other sites will be labeled 2/3, etc.) Titles may not exceed 200 characters in length, including the tag, e.g., 1/3, at the beginning of the title.

Cover Letter Attachment: The Cover Letter is one pdf file only. The following collaborative information is required in the Cover Letter: a listing of all the applications that are a part of the set of collaborative applications being submitted, including for each: 1) the PD/PI(s) name(s), 2) the Title (including the tag, e.g., "1/3"), and 3) the Applicant Institution. Each site should submit an identical listing.

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed. 

Biographical Sketch:

The application should document their inclusion of urology and/or nephrology and statistical research expertise, and prior experience with large scale clinical studies and RCTs.  Personnel should indicate their ability to build and lead multidisciplinary teams.

R&R Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.  

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Research Strategy:

The application from each site must contain a Research Strategy that clearly describes those aspects of the project that are common to all sites of the collaboration. All variations in the Research Strategy between sites, no matter how minor, should be highlighted in a subsection of the Research Strategy with the heading "Elements Unique to This Site." In this subsection, PDs/PIs should describe, for example, how the research site has a unique role in the collaboration, such as data coordination, statistical analyses, (etc).

The common Research Strategy section should include:

  • A discussion of the significance of the problem being studied, the need for the studies, and the potential impact of the results of the studies, as well as how the studies will test the hypothesis(es) proposed;
  • A concise description of the overall strategy, methodology and analyses to be used to accomplish the goals and specific aims of the study;
  • A description of and rationale for the proposed study designs;
  • A description of the interventions to be tested and the protocols to be followed, including a discussion of potential biases or challenges in the protocols and how they will be addressed;
  • Statistical methods that are appropriate for the study designs, including sample size and power calculations and the underlying assumptions (and data) used to link these calculations to the endpoints and to the hypothesis(es) being tested;
  • A discussion of studies that led to the proposed clinical studies and information or data from preliminary studies that address the need for and the feasibility of the studies; and
  • A brief acknowledgement of the responsibilities as part of a multi-center collaborative project.

In this section, there should be sufficient description of the items listed above to permit thorough evaluation of the proposed studies. Technical details contained in the clinical trial synopsis, statistical analysis plan, and data and safety monitoring plan can be referenced from within the Research Strategy section, in order to avoid duplicating text.

A application for the Scientific Data Research Center must:

  • Propose study designs potentially incorporating mobile health technology, behavioral economics or other innovative strategies, and analytical approaches to accomplish the goals of the FOA.
  • Present experience of the team as a whole with a wide range of studies including RCTs, observational studies, pragmatic trials and biomarker studies.
  • Present a plan for coordination of biosample (e.g. serum, DNA, stone, tissue, feces and urine) collection, storage, quality control and distribution; and interaction with the NIDDK Repositories for eventual transfer of data and clinical samples
  • Present a plan to work collaboratively with the Clinical Center investigators in the planning, implementation and analysis of all major studies
  • Describe the roles, responsibilities and interactions of the SDRC investigators with a leadership plan

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modifications:

  • Scientific Data Research Center applications should address a Data Sharing Plan.
  • USDRN investigators are expected to share their findings with the scientific community through scientific presentations and publications.
  • All USDRN-derived data and biological samples are expected to be provided to the NIDDK Data and Sample Repositories in accordance with Institute guidelines, consistent with achieving the goals of the program.

Appendix:  Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

Planned Enrollment Report

When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide. 

PHS 398 Cumulative Inclusion Enrollment Report

When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.

Foreign Institutions

Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

3. Submission Dates and Times

See Part I. Section III.1 for information regarding the requirements for obtaining a Dun and Bradstreet Universal Numbering System (DUNS) Number and for completing and maintaining an active System for Award Management (SAM) registration. Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

4. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

5. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

6. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

In order to expedite review, applicants are requested to notify the NIDDK Referral Office by email at calvof@mail.nih.gov when the application has been submitted. Please include the FOA number and title, PD/PI name, and title of the application.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-13-030.

Section V. Application Review Information
1. Criteria

Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?  

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? Do the SDRC key investigators have documented urologic/nephrologic expertise? Does the SDRC have expertise in ensuring scientific integrity and robustness of the clinical research studies? Does the SDRC have expertise in design, biostatistics, implementation, adherence, and data quality? Is there evidence of experience in analyzing data from RCTs, observational studies, pragmatic studies and biomarker studies? Do SDRC key investigators have a track-record of research productivity and cooperation within a broad, multi-site research effort? Does the SDRC provide evidence of sufficient expertise to address potential operational requirements of the USDRN, including the coordination of all meetings, agendas, conference calls, tracking of publications, protocol development, data collection and storage, website development and maintenance, preparation of reports and analyses for presentation to the investigators and the Data and Safety Monitoring Board, development of systems for data sharing, and other operational activities? Is sufficient expertise in place for the coordination of biosample collection, storage, quality control and distribution (e.g. serum, stone, DNA, tissue, feces and urine)?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Does the SDRC propose innovative approaches to the scientific question(s), research design, biostatistics, data quality, implementation, or data analysis efforts?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?  Does the SDRC propose research study designs and analytical approaches to achieve the goals of this FOA? Has the SDRC provided adequate evidence to plan and conduct biostatistical analyses for the needs of the USDRN potentially incorporating mobile health technology, behavioral economics or other innovative strategies? Does the SDRC proposed process for administration of the USDRN Ancillary Studies program appear adequate? Does the research plan describe the roles, responsibilities of the key investigators with a leadership plan? Does the research plan address integration, communication, resource and data sharing across the USDRN and ultimately provide relevant materials to the NIDDK Data and Biorepositories?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?  

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?   

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Protections for Human Subjects

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and Children 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

Not Applicable

 
Renewals

Not Applicable

Revisions

Not Applicable

 
Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genomic Wide Association Studies (GWAS) /Genomic Data Sharing Plan.

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIDDK, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

  • May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
  • Will receive a written critique.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Diabetes and Digestive and Kidney Diseases Advisory Council (NDDKAC). The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.
3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information
1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee's business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General  and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and NIH grant administration policies. The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

1. Developing the research design and study protocol, including definition of objectives and approaches, sample size and power calculations, and establishing procedures for participant recruitment and follow-up, data collection, quality control, interim data and safety monitoring, final data analysis and interpretation, and publication of results.

2. Establishing a Steering Committee to implement, coordinate and manage the project(s). Awardee(s) will name investigators to serve as members on a Steering Committee and other subcommittees, as appropriate, meeting periodically. Awardees will be required to accept and implement the common protocol(s) and procedures approved by the Steering Committee.

3. Designating Protocol Chairs. The Program Directors/Principal Investigators (for studies involving multiple protocols) shall designate a single Protocol Chairperson (if the Program Director/Principal Investigator does not assume this role) for each protocol to be carried out by the study group. The Protocol Chairperson shall function as the scientific coordinator for the protocol and shall assume responsibility for obtaining approval to implement the protocol from the Steering Committee and for developing and monitoring the protocol. Significant modifications to approved protocols must be approved by the Steering Committee.

4. Implementing collection of data specified by the study protocol. For a multi-center study, each awardee/site is required to ensure that data will be submitted expeditiously to the Scientific Data Research Center. Additionally, individual investigators/sites must demonstrate the ability to implement the strategy specifically designed for their individual study population.

5. Establishing procedures for data quality and completeness. Awardees are responsible for ensuring accurate and timely assessment of the progress of each study, including development of procedures to ensure that data collection and management are: (1) adequate for quality control and analysis; (2) for clinical trials, as simple as appropriate in order to facilitate cooperation/referral of study participants by physicians to avoid unnecessary expense; and (3) sufficiently staffed across the participating institutions. For research involving multiple sites, a plan for analysis of pooled data will be developed by the Steering Committee.

6. Submitting interim progress reports, when requested, to the NIDDK Program Official including as a minimum, summary data on protocol performance. For coordinated multiple awards or a multi-site single award, the NIDDK Program Official may require additional information from individual awardees/sites. Such reports are in addition to the required annual noncompeting continuation progress report.

7. Establishing procedures, where applicable, for all participating institutions in coordinated awards to comply with FDA regulations for studies involving investigational agents or devices and to comply with the requirements of 45 CFR Part 46 for the protection of human subjects, and the NIH policy requirements for the inclusion of women, minorities and children.

8. Reporting of the study findings. Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies. The awardee must also be adherent to Study Publication and Presentation Policy. The NIDDK will have access to and may periodically review all data generated under an award. NIDDK staff may co-author publications of findings with awardees consistent with NIH and study policies.

9. Support or other involvement of industry or any other third party in the study -- e.g., participation by the third party; involvement of study resources or citing the name of the study or NIDDK support; or special access to study results, primary data/summary information, or resources -- may be advantageous and appropriate. However, except for licensing of patents or copyrights, support or involvement of any third party is permitted only after concurrence by NIDDK.

10. Study investigators are encouraged to publish and to release publicly and disseminate results and other products of the study, in accordance with study protocols and steering committee policies on publications.

11. Maintaining confidentiality of information: The awardee(s) will maintain the confidentiality of the information developed by the investigators (i.e., protocols, data analysis, conclusions, etc.) as well as proprietary information of a company collaborating with the study.

12. The NIDDK has established Central Biosample, Genetic, and Data Repositories for the archiving and storage of data and biosamples collected in large, multi-site studies funded by NIDDK. The PI or his/her designee will coordinate with the NIDDK Data Repository to prepare the collected data for eventual archiving and distribution. In addition, if applicable, the PI or his/her designee will work with the NIDDK Biosample Repository to coordinate procedures for coding, shipping, processing, receipt, and storage of study samples that are to be maintained in the Repository. All samples and data transferred to the Repositories will be under the custodianship of the NIDDK, although the study's Steering Committee will have proprietary control of and exclusive access to the samples and data for an agreed-upon period of time. Subsequently samples and data will be available to the wider scientific community in accordance with the NIH policy on Data Sharing (https://grants.nih.gov/grants/policy/data_sharing/   and https://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm), as well as the NIDDK policy for data sharing in multi-center and large single-center clinical studies http://www.niddk.nih.gov/research-funding/process/human-subjects-research/Documents/PublicversionNIDDKdatasharingpolicy2013July2013.pdf.

13. The Food and Drug Administration Amendments Act of 2007 (FDAAA or US Public Law 110-85) was passed on September 27, 2007. The law requires mandatory registration and results reporting for certain clinical trials of drugs, biologics, and devices. If trials conducted under this grant are applicable clinical trials subject to FDAAA, the sponsor or his/her designee will perform the mandatory study registration and reporting of study results to ClinicalTrials.gov. For more information about this law and requirements for sponsors and/or investigators, visit the PRS and U.S. Public Law 110-85 Information Page at https://clinicaltrials.gov/ct2/manage-recs/fdaaa. In addition, grantees should be aware that clinical trials not covered by FDAAA may still require registration in an approved registry in order to be published, according to the guidelines issued by the International Committee of Medical Journal Editors (http://icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html).

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

An NIDDK Project Scientist with substantial involvement will:

1. Serve as the contact point for all facets of the scientific interaction with the awardee (s). As required for the coordination of activities and to expedite progress, NIDDK may designate additional NIDDK staff to provide advice to the awardee on specific scientific and/or analytic issues. Such staff may include another Project Scientist or Project Coordinator, who will provide direct technical assistance to the awardees to optimize the conduct and/or analysis of the study; or who may assist in the coordination of activities across multiple sites.

2. For multi-center studies, participate in the Steering Committee that oversees study conduct. The NIDDK Project Scientist or Project Coordinator will be a full participant and voting member of the Steering Committee and, if applicable, subcommittees.

3. Serve as a resource to study investigators with respect to other ongoing NIDDK activities that may be relevant to the study to facilitate compatibility with the NIDDK missions and avoid unnecessary duplication of effort.

4. Have substantial involvement assisting in the design and coordination of research activities for awardees as elaborated below:

a. Assisting by providing advice in the management and technical performance of the investigations, coordinating required regulatory clearances for investigational agents used in the study, which are held by NIDDK. The NIDDK may reserve the right to cross file or independently file an Investigational New Drug Application or an Investigational Device Exemption form with the FDA.

b. The NDDK Project Scientist or Project Coordinator may coordinate activities among awardees by assisting in the design, development, and coordination of a common research or clinical protocol and statistical evaluations of data; in the preparation of questionnaires and other data recording forms; and in the publication of results.

c. Reviewing procedures for assessing data quality and study performance monitoring.

d. The NIDDK Project Scientist or Project Coordinator may be co-authors on study publications. In general, to warrant co-authorship, NIDDK staff must have contributed to the following areas: (a) design of the concepts or experiments being tested; (b) performance of significant portions of the activity; (c) participation in analysis and interpretation of study results and (d) preparation and authorship of pertinent manuscripts.

The NIDDK Program Official identified in the Notice of Award will:

1. Interact with the Program Director(s)/Principal Investigator(s) on a regular basis to monitor study progress. Monitoring may include: regular communications with the Program Director/Principal Investigator and staff, periodic site visits, observation of field data collection and management techniques, quality control, fiscal review, and other relevant matters; as well as attendance at Steering Committee, data safety and monitoring board, and related meetings. The NIDDK retains, as an option, periodic review of progress by researchers not involved with the study.

2. Review and approve protocols prior to implementation to insure they are within the scope of peer review, for safety considerations, as required by Federal regulations.

3. The NIDDK Program Official will monitor protocol progress, and may request that a protocol study be closed to accrual for reasons including: (a) accrual rate insufficient to complete study in a timely fashion; (b) accrual goals met early; (c) poor protocol performance; (d) patient safety and regulatory concerns; (e) study results that are already conclusive; (f) low likelihood of showing a benefit of the intervention (futility); and (g) emergence of new information that diminishes the scientific importance of the study question. The NIDDK will not permit further expenditures of NIDDK funds for a study after requesting closure except as specifically approved by the NIDDK.

4. Make recommendations for continued funding based on: a) overall study progress, including sufficient patient and/or data accrual; b) cooperation in carrying out the research (e.g., attendance at Steering Committee meetings, implementation of group decisions, compliance with the terms of award and reporting requirements); and/or c) maintenance of a high quality of research, which will allow pooling of data and comparisons across multiple cooperative agreement awards for common data elements.

5. Appoint a Data and Safety Monitoring Board (DSMB) as appropriate; the NIDDK Program Official or their Project Coordinator will serve as the Executive Secretary and/or NIDDK program representative on the DSMB.

Areas of Joint Responsibility include:

 In addition to the interactions defined above, NIDDK Project Scientist and Awardees shall share responsibility for the following activities:

1. Steering Committee.

A Steering Committee organized by the study investigator(s) will be the main governing body of the study.

The Steering Committee has primary responsibility to design research activities, establish priorities, develop common protocols and manuals, questionnaires and other data recording forms, establish and maintain quality control among awardees, review progress, monitor patient accrual, coordinate and standardize data management, and cooperate on the publication of results. Major scientific decisions regarding the core data will be determined by the Steering Committee. The Steering Committee will document progress in written reports to the NIDDK Program Official, and will provide periodic supplementary reports upon request.

The Steering Committee will be composed of all Program Director(s)/Principal Investigator(s), and co-investigators as deemed necessary, and the NIDDK Project Scientist. The final structure of the Steering Committee and voting procedures will be established at the first meeting. The NIDDK Project Scientist will have voting membership on the Steering Committee, and as appropriate, its subcommittees. The frequency of Steering Committee meetings will be dictated by a vote of the members of the Steering Committee.

A Chairperson of the Steering Committee, other than the NIDDK Project Scientist, will be selected by the NIDDK. The Chairperson provides leadership to the Committee by conducting the Steering Committee meetings, representing the study group to the External Oversight Committee established by the NIDDK and by interacting closely with the awardees during protocol development and implementation.

2. External Study Oversight.

An independent Data and Safety Monitoring Board will be established by the NIDDK for Phase III clinical trials or other high risk studies as appropriate. An Observational Study Monitoring Board (OSMB) will be established for observational/epidemiologic studies. These Boards will review study progress, safety data and interim results, as appropriate, and provide guidance to the NIDDK.

Dispute Resolution

Any disagreement that may arise on scientific/programmatic matters (within the scope of the award), between award recipients and the NIDDK may be brought to dispute resolution. A dispute resolution panel will be composed of three members --one selected by the awardee (or the Steering Committee, with the NIDDK member not voting), a second member selected by NIDDK, and the third member elected by the two prior selected members. These special dispute resolution procedures in no way affect the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulations at 42 CFR Part 50, Subpart D, and HHS regulations at 45 CR Part 16.

3. Reporting

When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000.  See the NIH Grants Policy Statement for additional information on this reporting requirement.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Commons Help Desk (Questions regarding eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Finding Help Online: https://grants.nih.gov/support/ (preferred method of contact)

Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact CenterTelephone: 800-518-4726
Email: support@grants.gov

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)

Telephone: 301-710-0267

Scientific/Research Contact(s)

Ziya Kirkali, M.D.
National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-7718
Email: kirkaliz@mail.nih.gov

Peer Review Contact(s)

Jason D. Hoffert, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-496-9010
Email: jason.hoffert@nih.gov

Financial/Grants Management Contact(s)

Carolyn Kofa-Sullivan
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-7687
Email: kofac@mail.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.